Activity of the Vascular-disrupting Agent 5,6-dimethylxanthenone-4-acetic Acid Against Human Head and Neck Carcinoma Xenografts

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2006 Jul 27

PMID 16867215

Citations 26

Authors

Mukund Seshadri

Richard Mazurchuk

Joseph A Spernyak

Arup Bhattacharya

Youcef M Rustum

David A Bellnier

Affiliations

Soon will be listed here.

Abstract

Head and neck squamous cell carcinomas (HNSCC) constitute a majority of the tumors of the upper aerodigestive tract and continue to present a significant therapeutic challenge. To explore the potential of vascular-targeted therapy in HNSCC, we investigated the antivascular, antitumor activity of the potent vascular-disrupting agent (VDA) 5,6-dimethylxanthenone-4-acetic acid (DMXAA) against two HNSCC xenografts with markedly different morphologic and vascular characteristics. Athymic nude mice bearing subcutaneous FaDu (human pharyngeal squamous cell carcinoma) and A253 (human submaxillary gland epidermoid carcinoma) tumors were administered a single dose of DMXAA (30 mg/kg, i.p). Changes in vascular function were evaluated 24 hours after treatment using contrast-enhanced magnetic resonance imaging (MRI) and immunohistochemistry (CD31). Signal enhancement (E) and change in longitudinal relaxation rates (deltaR1) were calculated to measure alterations in vascular perfusion. MRI showed a 78% and 49% reduction in vascular perfusion in FaDu and A253 xenografts, respectively. CD31-immunostaining of tumor sections revealed three-fold (FaDu) and two-fold (A253) reductions in microvessel density (MVD) 24 hours after treatment. DMXAA was equally effective against both xenografts, with significant tumor growth inhibition observed 30 days after treatment. These results indicate that DMXAA may be clinically beneficial in the management of head and neck cancers, alone or in combination with other treatments.

Citing Articles

Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck cancer treatment.

Fabbrizi M, Parsons J Cancer Drug Resist. 2022; 3(4):775-790.

PMID: 35582232 PMC: 8992550. DOI: 10.20517/cdr.2020.49.

Monitoring the therapeutic efficacy of CA4P in the rabbit VX2 liver tumor using dynamic contrast-enhanced MRI.

Han T, Duan Q, Yang R, Wang Y, Yin H, Meng F Diagn Interv Radiol. 2021; 27(5):587-594.

PMID: 34559047 PMC: 8480957. DOI: 10.5152/dir.2021.20010.

In Vivo Tumor Vascular Imaging with Light Emitting Diode-Based Photoacoustic Imaging System.

Xavierselvan M, Singh M, Mallidi S Sensors (Basel). 2020; 20(16).

PMID: 32806575 PMC: 7472236. DOI: 10.3390/s20164503.

Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response.

Folaron M, Merzianu M, Duvvuri U, Ferris R, Seshadri M Cancers (Basel). 2019; 11(7).

PMID: 31284584 PMC: 6679003. DOI: 10.3390/cancers11070951.

Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis.

Aalinkeel R, Nair B, Chen C, Mahajan S, Reynolds J, Zhang H Immunology. 2016; 148(4):387-406.

PMID: 27159450 PMC: 4948039. DOI: 10.1111/imm.12618.

References

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Cohen E, Lingen M, Vokes E . The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004; 22(9):1743-52. DOI: 10.1200/JCO.2004.06.147. View

Beauregard D, Pedley R, Hill S, Brindle K . Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed. 2002; 15(2):99-105. DOI: 10.1002/nbm.723. View

Siemann D, Mercer E, Lepler S, Rojiani A . Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer. 2002; 99(1):1-6. DOI: 10.1002/ijc.10316. View

Galbraith S, Rustin G, Lodge M, Taylor N, Stirling J, Jameson M . Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol. 2002; 20(18):3826-40. DOI: 10.1200/JCO.2002.09.144. View

Sanderson R, Ironside J . Squamous cell carcinomas of the head and neck. BMJ. 2002; 325(7368):822-7. PMC: 1124330. DOI: 10.1136/bmj.325.7368.822. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

RANGAN S . A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer. 1972; 29(1):117-21. DOI: 10.1002/1097-0142(197201)29:1<117::aid-cncr2820290119>3.0.co;2-r. View

Fogh J, FOGH J, Orfeo T . One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977; 59(1):221-6. DOI: 10.1093/jnci/59.1.221. View

10.

Schmiedl U, Ogan M, Moseley M, Brasch R . Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: and experimental study in rats. AJR Am J Roentgenol. 1986; 147(6):1263-70. DOI: 10.2214/ajr.147.6.1263. View

11.

Schmiedl U, Ogan M, Paajanen H, Marotti M, Crooks L, Brito A . Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. Radiology. 1987; 162(1 Pt 1):205-10. DOI: 10.1148/radiology.162.1.3786763. View

12.

Aicher K, Dupon J, White D, Aukerman S, Moseley M, JUSTER R . Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha. Cancer Res. 1990; 50(22):7376-81. View

13.

Rewcastle G, Atwell G, Li Z, Baguley B, Denny W . Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem. 1991; 34(1):217-22. DOI: 10.1021/jm00105a034. View

14.

Denekamp J . Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990; 9(3):267-82. DOI: 10.1007/BF00046365. View

15.

Pedley R, Boden J, Boden R, Boxer G, Flynn A, Keep P . Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res. 1996; 56(14):3293-300. View

16.

Joseph W, Cao Z, Mountjoy K, Marshall E, Baguley B, Ching L . Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res. 1999; 59(3):633-8. View

17.

Bhattacharya A, Toth K, Mazurchuk R, Spernyak J, Slocum H, Pendyala L . Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res. 2004; 10(23):8005-17. DOI: 10.1158/1078-0432.CCR-04-1306. View

18.

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

19.

Seiwert T, Cohen E . State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 2005; 92(8):1341-8. PMC: 2361996. DOI: 10.1038/sj.bjc.6602510. View

20.

Gibson M, Li Y, Murphy B, Hussain M, DeConti R, Ensley J . Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23(15):3562-7. DOI: 10.1200/JCO.2005.01.057. View